Romilly Life Sciences’ Post

The #pharmaceutical landscape is growing more volatile, due to increased #hospital consolidation, a tightening #regulatory environment and continued downward economic pressures. Collectively, they pose great challenges for an industry in the throes of painful transition. Our Numerof & Associates Global Pharma Outlook calls for more difficult days ahead. As global regulatory requirements create new barriers for product market entry, payers clamp down on new products, physician clout diminishes and public distrust of the industry and government scrutiny reaches new highs, manufacturers must shift to a new commercial model. In my latest Forbes column, I discuss the forces that will continue to intensify in 2024 and what the implications are for the commercial strategy going forward. #Pharma #PharmaceuticalCompanies #CommercialModel #Healthcare 

Thank you Rita Numerof, PhD for the insightful article in Forbes highlighting the many complexities facing our healthcare delivery model and the pharmaceutical industry.

Check out this article from Pharma Tech Outlook, in which Melissa Lore, Chief Compliance Officer, FFF Enterprises (a HITLAB Sponsor) shares insight on the latest trends and challenges in the pharmaceutical industry and how they transform the way organizations operate in the field. https://lnkd.in/emwyTSYC

Wanted to shake things up this week (slightly)! Let's talk about what makes pharma companies unique: How should a company be run if it spends nearly a quarter of its revenue on R&D? Should you spend that much on R&D? What happens if you don’t? Is M&A a cheat code? This week - I briefly explore a case where choosing short-term growth and profits over patients-needs led to a major management fumble, lawsuits and a huge loss of public trust.

Our latest CG Pharma Commercialization Services report is finally here and it is packed with all the latest insights and trends you need to know about M&A in the sector! In this edition, we take a deep dive into deal activity over the past six months and share some truly fantastic insights from none other than industry expert, Nick Sullivan Whether you're in the thick of the pharma commercialization world or just curious about where the market is headed, this report is a must-read Happy reading! #Pharma #Commercialization #IndustryInsights #PharmaDeals #HealthcareM&A David Sanders Kunal Kadiwar Tom O'Connor Matthew Kebel Cameron Brodeur Beatrice Meadowcroft Canaccord Genuity Group Inc.

Exceptional Business Opportunity: Premier Clinical Trials Services Company for Sale https://lnkd.in/gPs7UQEn Are you ready to lead a pioneering force in the clinical trials industry? We are presenting an exclusive opportunity to acquire a distinguished provider of clinical trials services, a beacon in the industry for over 20 years. This company is renowned as Australia’s only local independent provider, offering a suite of secure, integrated, and fully validated solutions that support the global pharmaceutical sector. What Sets This Business Apart? Specialised Services: Offering cutting-edge Patient Randomisation with advanced IVRS and Web solutions, efficient Drug Supply Management, comprehensive Patient Diaries, and streamlined Payment Management. Proven Excellence: A solid track record of two decades in the clinical trials market. Market Exclusivity: The sole independent provider in Australia equipped with proprietary technology. Global Expansion Potential: Tremendous opportunities to scale operations internationally with strategic marketing initiatives, building on an existing base of word-of-mouth referrals. Growth Opportunities Despite its strong market presence, significant expansion potential remains, especially in international markets. The business has thrived on minimal marketing, suggesting vast potential for growth through enhanced marketing strategies and business development efforts. Ideal Candidate This business is perfectly positioned for an existing scientific data management company looking to broaden its services, or a stellar entry point for professionals or organisations involved in clinical research looking to make a substantial impact. Investment Considerations The owners are seeking offers starting at $150,000 from suitably qualified individuals or businesses eager to take the reins of a reputable and robustly established service provider in the clinical trials sector. Don’t miss this unique opportunity to own a key player in a vital industry. For more details or to discuss this investment further, please reach out: Scott Ker  Co-Founder & Managing Director  M: 0499 028 881 P: 1300 378 041 [email protected]  https://lnkd.in/duzm8KTB www.mbsadvisory.com.au Take the step towards owning a business with a solid foundation, ready for exponential growth. #BusinessForSale #ClinicalTrials #HealthcareInvestment #BusinessOpportunity #Entrepreneurship #businessforsale #sydneybusinessforsale #businessbroker #sydneybusinessbroker

"early-stage life sciences companies and their investors should anticipate and prepare for regulatory and compliance scrutiny of the following key areas in diligence for public and private capital raising" 1. Regulatory Pathways 2. Clinical Trials 3. GMP & Contract Manufacturing 4. Coverage and Reimbursement 5. Compliance Programs 6. Transparency Reporting Preparedness 7. ESG 8. Supply Chain #regulatoryaffairs #FDA #biotech #pharmaceutical #productdevelopment #startup #lifesciences #clinical #clinicaldevelopment #preclinical #medicalwriting #CMC #eCTD 

Pharmaceuticals and life sciences and healthcare services M&A is expected to accelerate in 2024, as innovative companies that can drive value attract investor interest. Read more in our M&A outlook: https://pwc.to/3S6JONI #PwCDeals #ValueCreation Ronald Chopoorian, Christian K. Moldt, Sujay Shetty, Christine Walters